Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

HU users were more likely to be prescribed folic acid (76% vs. 52%, p < 0.001), vitamin D3 (61% vs. 40%, p < 0.001), and calcium (40% vs. 23%, p < 0.001) but less likely to have iron supplements (5% vs. 9%, p < 0.001) compared to non-users (Table 1).

Source: 3.1. Characteristics of the Cohort. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were classified based on their age into eight different groups (18 to 25, 26 to 35, 36 to 45, 46 to 55, 56 to 65, 66 to 75, 76 to 85, 86 to 95 years) to help in assessing the difference in the pattern of hydroxyurea prescribing among these groups of patients.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Prescribing Hydroxyurea in Sickle Cell Disease Patients: The Pattern and Association with Co-Prescribed Medications Used to Manage the Disease Complications

Study design awaiting verification · Journal of Clinical Medicine · 2024

Original publication title

Prescribing Hydroxyurea in Sickle Cell Disease Patients: The Pattern and Association with Co-Prescribed Medications Used to Manage the Disease Complications

Nida Alsaffar; Mohammed Ali Alsaleh; Abdulmonem Ali Alsaleh; Neda Z. Ghanem; Mohammad Hussain Al khamees; Mohammed A. Alqurain; Jenan Almatouq; Bader AlAlwan; Aymen A. Alqurain

© 2024 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background and Objectives:

Hydroxyurea (HU) is an effective medication used to reduce the frequency of painful crises associated with sickle cell disease (SCD). However, data describing its prevalence among SCD patients in the Eastern Region of Saudi Arabia are scarce. This is a multi-center, retrospective, cross-sectional study that aims to investigate the pattern of prescribing HU in SCD patients and to determine the association between prescribing HU and other co-prescribed medications used to manage SCD complications.

Methods:

Data were collected from patients who visited the hematology clinics of Al-Qatif Central Hospital (QCH) and King Fahad Hospital in Hofuf (KFHH) between June 2021 to May 2023. The data included demographics, prescribed medications, and recent laboratory test results, all of which were collected from patients’ medical records. Descriptive statistics were utilized to assess the difference between HU users vs. non-users. A binary logistic regression model was used to determine the association between prescribing HU and co-prescribed medications used to manage SCD complications. The results are presented as the odds ratio (OR) and 95% confidence interval (95% CI).

Results:

This study included 2816 SCD patients with a 56% prevalence of HU prescription. HU was prescribed for young age groups more often compared to old age group patients. Young males were more likely to be prescribed with HU compared to females, and it becomes dominant in females after the age of 36. HU users were more likely to have paracetamol (69% vs. 53%, OR = 1.9, 95% CI 1.6 to 2.2), NSAIDs (50% vs. 35%, OR = 1.7, 95% CI 1.5 to 2), and opioids (41% vs. 37%, OR = 1.3, 95% CI 1.1 to 1.6) co-prescribed, and less often to have laxatives (8% vs. 5%, OR = 0.66, 95% CI 0.48 to 0.9) and anticoagulants (22% vs. 15%, OR = 0.56, 95% CI 0.46 to 0.68) co-prescribed compared to non-users.

Conclusions:

The pattern of prescribing HU, supported by the association findings, raises concerns about patients’ compliance and adherence to HU therapy. Early health education, specifically to young female SCD patients, is warranted to increase the success rate of HU therapy.

An extract from the source publication. Read it in context.

At a glance

Abstract: Background and Objectives

Hydroxyurea (HU) is an effective medication used to reduce the frequency of painful crises associated with sickle cell disease (SCD). However, data describing its prevalence among SCD patients in the Eastern Region of Saudi Arabia are scarce. This is a multi-center, retrospective, cross-sectional study that aims to investigate the pattern of prescribing HU in SCD patients and to determine the association between prescribing HU and other co-prescribed medications used to manage SCD complications.

Source: Background and Objectives:

Abstract: Results

This study included 2816 SCD patients with a 56% prevalence of HU prescription. HU was prescribed for young age groups more often compared to old age group patients. Young males were more likely to be prescribed with HU compared to females, and it becomes dominant in females after the age of 36. HU users were more likely to have paracetamol (69% vs. 53%, OR = 1.9, 95% CI 1.6 to 2.2), NSAIDs (50% vs. 35%, OR = 1.7, 95% CI 1.5 to 2), and opioids (41% vs. 37%, OR = 1.3, 95% CI 1.1 to 1.6) co-prescribed, and less often to have laxatives (8% vs. 5%, OR = 0.66, 95% CI 0.48 to 0.9) and anticoagulants (22% vs. 15%, OR = 0.56, 95% CI 0.46 to 0.68) co-prescribed compared to non-users.

Source: Results:

Abstract: Conclusions

The pattern of prescribing HU, supported by the association findings, raises concerns about patients’ compliance and adherence to HU therapy. Early health education, specifically to young female SCD patients, is warranted to increase the success rate of HU therapy.

Source: Conclusions:
Authors’ abstract

Background and Objectives:

Hydroxyurea (HU) is an effective medication used to reduce the frequency of painful crises associated with sickle cell disease (SCD). However, data describing its prevalence among SCD patients in the Eastern Region of Saudi Arabia are scarce. This is a multi-center, retrospective, cross-sectional study that aims to investigate the pattern of prescribing HU in SCD patients and to determine the association between prescribing HU and other co-prescribed medications used to manage SCD complications.

Methods:

Data were collected from patients who visited the hematology clinics of Al-Qatif Central Hospital (QCH) and King Fahad Hospital in Hofuf (KFHH) between June 2021 to May 2023. The data included demographics, prescribed medications, and recent laboratory test results, all of which were collected from patients’ medical records. Descriptive statistics were utilized to assess the difference between HU users vs. non-users. A binary logistic regression model was used to determine the association between prescribing HU and co-prescribed medications used to manage SCD complications. The results are presented as the odds ratio (OR) and 95% confidence interval (95% CI).

Results:

This study included 2816 SCD patients with a 56% prevalence of HU prescription. HU was prescribed for young age groups more often compared to old age group patients. Young males were more likely to be prescribed with HU compared to females, and it becomes dominant in females after the age of 36. HU users were more likely to have paracetamol (69% vs. 53%, OR = 1.9, 95% CI 1.6 to 2.2), NSAIDs (50% vs. 35%, OR = 1.7, 95% CI 1.5 to 2), and opioids (41% vs. 37%, OR = 1.3, 95% CI 1.1 to 1.6) co-prescribed, and less often to have laxatives (8% vs. 5%, OR = 0.66, 95% CI 0.48 to 0.9) and anticoagulants (22% vs. 15%, OR = 0.56, 95% CI 0.46 to 0.68) co-prescribed compared to non-users.

Conclusions:

The pattern of prescribing HU, supported by the association findings, raises concerns about patients’ compliance and adherence to HU therapy. Early health education, specifically to young female SCD patients, is warranted to increase the success rate of HU therapy.

Publication and source details

Original title: Prescribing Hydroxyurea in Sickle Cell Disease Patients: The Pattern and Association with Co-Prescribed Medications Used to Manage the Disease Complications

Nida Alsaffar; Mohammed Ali Alsaleh; Abdulmonem Ali Alsaleh; Neda Z. Ghanem; Mohammad Hussain Al khamees; Mohammed A. Alqurain; Jenan Almatouq; Bader AlAlwan; Aymen A. Alqurain

Journal of Clinical Medicine · 2024

* Correspondence: b.alalwan@machs.edu.sa (B.A.); aymen.alqurain@nbu.edu.sa (A.A.A.)© 2024 by the authors.2024https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Deanship of Scientific Research at Northern Border University, Arar, KSANBU-FFR-2024-396-01The authors extend their appreciation to the Deanship of Scientific Research at Northern Border University, Arar, KSA, for funding this research work through the project number NBU-FFR-2024-396-01.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T08:55:23.402737+00:00

DOI: 10.3390/jcm13206254 · PMC11508296